Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.46 |
| ▸ | HSD11B2 | P80365 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23924201 | 1.00 | HSD11B1 (0.46) | HSD11B1HSD11B2ALDH1A1TSHRGRM2 | |
| SCHEMBL14801335 | 0.90 | HSD11B1 (0.41) | HSD11B1HSD11B2 | |
| SCHEMBL14801336 | 0.90 | HSD11B1 (0.41) | HSD11B1HSD11B2 | |
| SCHEMBL14801334 | 0.90 | HSD11B1 (0.41) | HSD11B1HSD11B2 | |
| SCHEMBL23924375 | 0.82 | TSHR (0.33) | HSD11B1HSD11B2TSHR | |
| SCHEMBL23924373 | 0.82 | TSHR (0.33) | HSD11B1HSD11B2TSHR | |
| SCHEMBL23951358 | 0.78 | PDE4B (0.46) | HSD11B1HSD11B2ALDH1A1 | |
| SCHEMBL23923814 | 0.78 | PDE4B (0.46) | HSD11B1HSD11B2ALDH1A1 | |
| SCHEMBL23923813 | 0.78 | PDE4B (0.46) | HSD11B1HSD11B2ALDH1A1 | |
| SCHEMBL4022475 | 0.78 | HSD11B1 (0.61) | HSD11B1HSD11B2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | HSD11B1 1323/4885HSD11B2 1016/4885ALDH1A1 2328/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | HSD11B1 1323/4885HSD11B2 1016/4885ALDH1A1 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.